| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SB52334 | GDSC1000 | pan-cancer | AAC | 0.092 | 0.008 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.008 |
| mRNA | AR-42 | GDSC1000 | pan-cancer | AAC | 0.083 | 0.008 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.08 | 0.008 |
| mRNA | GW843682X | CTRPv2 | pan-cancer | AAC | 0.093 | 0.009 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.088 | 0.009 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.094 | 0.009 |
| mRNA | AZD6482 | GDSC1000 | pan-cancer | AAC | -0.086 | 0.009 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | 0.14 | 0.009 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.095 | 0.01 |